Protagenic Therapeutics, Inc. (PTIX)
- Previous Close
1.5600 - Open
1.6000 - Bid --
- Ask --
- Day's Range
1.3100 - 1.7000 - 52 Week Range
0.6800 - 2.3200 - Volume
6,604 - Avg. Volume
11,541 - Market Cap (intraday)
7.265M - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1500 - Earnings Date May 15, 2024 - May 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
www.protagenic.comRecent News: PTIX
Performance Overview: PTIX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTIX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTIX
Valuation Measures
Market Cap
6.96M
Enterprise Value
2.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.90
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.43
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.78%
Return on Equity (ttm)
-94.48%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5M
Diluted EPS (ttm)
-1.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
4.06M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.47M